Cargando…
Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity
Immunotherapy has transformed cancer treatments; however, a large fraction of patients encounter resistance. Such resistance is mediated by complex factors, often involving interactions between multiple genes. Thus, it is crucially important to identify genetic interactions between genes that are si...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716677/ https://www.ncbi.nlm.nih.gov/pubmed/36456981 http://dx.doi.org/10.1186/s13045-022-01389-y |
_version_ | 1784842743775756288 |
---|---|
author | Park, Jonathan J. Codina, Adan Ye, Lupeng Lam, Stanley Guo, Jianjian Clark, Paul Zhou, Xiaoyu Peng, Lei Chen, Sidi |
author_facet | Park, Jonathan J. Codina, Adan Ye, Lupeng Lam, Stanley Guo, Jianjian Clark, Paul Zhou, Xiaoyu Peng, Lei Chen, Sidi |
author_sort | Park, Jonathan J. |
collection | PubMed |
description | Immunotherapy has transformed cancer treatments; however, a large fraction of patients encounter resistance. Such resistance is mediated by complex factors, often involving interactions between multiple genes. Thus, it is crucially important to identify genetic interactions between genes that are significantly mutated in cancer patients and those involved in immune responses, ideally the ones that currently have chemical compounds for direct targeting. To systematically interrogate such genetic interactions that mediate cancer cells’ response to T cell killing, we designed an asymmetric dual perturbation library targeting the matched combinations between significantly mutated tumor suppressors and immune resistance genes. We performed a combinatorial double knockout screen on 1159 gene pairs and identified those where joint loss-of-function renders altered cellular response to T cell cytotoxicity. We also performed comparative transcriptomics-based analyses on tumor and normal samples from TCGA and GTEx cohorts, mutational profiling analyses, and survival analyses to further characterize the significance of identified hits in clinical patients. Interactions between significantly mutated tumor suppressors and potentially druggable immune resistance genes may offer insights on potential new concepts of how to target clinically relevant cancer mutations with currently available agents. This study also provides a technology platform and an asymmetric double knockout library for interrogating genetic interactions between cancer mutations and immune resistance pathways under various settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01389-y. |
format | Online Article Text |
id | pubmed-9716677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97166772022-12-03 Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity Park, Jonathan J. Codina, Adan Ye, Lupeng Lam, Stanley Guo, Jianjian Clark, Paul Zhou, Xiaoyu Peng, Lei Chen, Sidi J Hematol Oncol Correspondence Immunotherapy has transformed cancer treatments; however, a large fraction of patients encounter resistance. Such resistance is mediated by complex factors, often involving interactions between multiple genes. Thus, it is crucially important to identify genetic interactions between genes that are significantly mutated in cancer patients and those involved in immune responses, ideally the ones that currently have chemical compounds for direct targeting. To systematically interrogate such genetic interactions that mediate cancer cells’ response to T cell killing, we designed an asymmetric dual perturbation library targeting the matched combinations between significantly mutated tumor suppressors and immune resistance genes. We performed a combinatorial double knockout screen on 1159 gene pairs and identified those where joint loss-of-function renders altered cellular response to T cell cytotoxicity. We also performed comparative transcriptomics-based analyses on tumor and normal samples from TCGA and GTEx cohorts, mutational profiling analyses, and survival analyses to further characterize the significance of identified hits in clinical patients. Interactions between significantly mutated tumor suppressors and potentially druggable immune resistance genes may offer insights on potential new concepts of how to target clinically relevant cancer mutations with currently available agents. This study also provides a technology platform and an asymmetric double knockout library for interrogating genetic interactions between cancer mutations and immune resistance pathways under various settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01389-y. BioMed Central 2022-12-01 /pmc/articles/PMC9716677/ /pubmed/36456981 http://dx.doi.org/10.1186/s13045-022-01389-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Correspondence Park, Jonathan J. Codina, Adan Ye, Lupeng Lam, Stanley Guo, Jianjian Clark, Paul Zhou, Xiaoyu Peng, Lei Chen, Sidi Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity |
title | Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity |
title_full | Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity |
title_fullStr | Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity |
title_full_unstemmed | Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity |
title_short | Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity |
title_sort | double knockout crispr screen for cancer resistance to t cell cytotoxicity |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716677/ https://www.ncbi.nlm.nih.gov/pubmed/36456981 http://dx.doi.org/10.1186/s13045-022-01389-y |
work_keys_str_mv | AT parkjonathanj doubleknockoutcrisprscreenforcancerresistancetotcellcytotoxicity AT codinaadan doubleknockoutcrisprscreenforcancerresistancetotcellcytotoxicity AT yelupeng doubleknockoutcrisprscreenforcancerresistancetotcellcytotoxicity AT lamstanley doubleknockoutcrisprscreenforcancerresistancetotcellcytotoxicity AT guojianjian doubleknockoutcrisprscreenforcancerresistancetotcellcytotoxicity AT clarkpaul doubleknockoutcrisprscreenforcancerresistancetotcellcytotoxicity AT zhouxiaoyu doubleknockoutcrisprscreenforcancerresistancetotcellcytotoxicity AT penglei doubleknockoutcrisprscreenforcancerresistancetotcellcytotoxicity AT chensidi doubleknockoutcrisprscreenforcancerresistancetotcellcytotoxicity |